Future Potential Treatments / Cures for Hair Loss

WIN 49596

Hair Loss Treatment Type: Antiandrogen (Androgen Receptor Blocker) Notes: WIN 49596 is a new androgen receptor blocker comparable to flutamide and casodex. It has been shown to be effective in early animal model studies.

GI197111X

Hair Loss Treatment Type: Dual 5-alpha reductase inhibitor in an oral softgel   Notes: GI197111X is a new dual 5-alpha reductase inhibitor which could be GlaxoSmithKline’s successor to Dutasteride / Avodart. Because Glaxo already has a potent dual 5-alpha reductase inhibitor on the market (Avodart), there is no reason to conduct Phase I or II   …Continue Reading

TZP-4238

Hair Loss Treatment Type: Antiandrogen Notes: TZP-4238 is a new potent anti-androgen that reduces DHT levels by 50% and blocks the androgen receptor by 60%. It also reduces testosterone levels.

SK&F 105657

Hair Loss Treatment Type: Antiandrogen Notes: SK&F 105657 is another antiandrogen being researched that appears promising.

RU 58841

Hair Loss Treatment Type: Antiandrogen   Notes: This is a French drug which is not yet FDA approved which has been shown to be a highly effective local topical antiandrogen. The company that makes the drug has shut down its dermatological division and is no longer pursuing new drugs from that division including RU58841. It   …Continue Reading

PTHrP Antagonists

Parathyroid hormone related peptide is a possible treatment for hair loss being investigated by Dr. Michael Holick of Boston University. He believes it is the key to hairs being turned on and off as well as other things. Hair Loss Treatment Type: Parathyroid Hormone related Peptide Antagonist Testing: Awaiting approval for human testing. Clinical Results:   …Continue Reading

MK-386

Hair Loss Treatment Type: Anti-androgen Notes: MK-386 is a relatively new anti-androgen that has been shown to inhibit ONLY type 1 DHT. It inhibits circulating DHT by 20-30%. In combination with Proscar, it reduced DHT by an average of 89%, compared with 68% by Proscar alone.

MK-0963

Hair Loss Treatment Type: Anti-androgen Notes: MK-0963 is a relatively new anti-androgen that has been shown to inhibit DHT by 78-80% on average (exceeding Proscar by 10% or more). In addition, at the maximal dosage (25mg), it suppressed DHT by at least 70% (still more than Proscar 5mg) for up to SIX days.

MK-0434

Hair Loss Treatment Type: Anti-androgen Notes: MK-0434 is a relatively new anti-androgen that has been shown to inhibit DHT up to 95%. In one study with men with BPH, the reduction was 50% with no adverse side effects.

LY191704

Hair Loss Treatment Type: Anti-androgen Notes: This treatment seems to be a promising anti-androgen, which inhibits only the type 1 isozyme of DHT found in skin/hair follicles.

ICI 182,780

Hair Loss Treatment Type: Estrogen Blocker Notes: Researchers at North Carolina University previously announced that an estrogen blocking drug they discovered promoted hair growth in mice models.

Hair Cloning (Culturing)

What is it? Hair culturing involves removing donor hairs from the back of the scalp, isolating the stem cells from which the follicle grows, and culturing (growing) them in a lab. Then the cells are re-implanted into the balding area of scalp. Because many stem cells are being grown in the lab from a few hairs, hair   …Continue Reading

Gene Therapy

Hair Loss Treatment Type: Recombinant DNA Gene Therapy Notes: This treatment represents the most likely “cure” for baldness. The end to daily treatments and a 100% response rate in everyone. The company “AntiCancer, Inc.” has developed a method for delivering good genes to the hair follicles. All that is needed are the good genes to   …Continue Reading

FK143

Hair Loss Treatment Type: Antiandrogen Notes: This is a new non-steroidal antiandrogen that seems to be a potent inhibitor of 5 alpha reductase (required to make DHT).

FCE 28260, 28175, 27837

Hair Loss Treatment Type: Antiandrogen Notes: These three substances appear to be potent inhibitors of both types of DHT.

Leo

An unnamed hair loss drug being researched by a Danish pharmaceutical company. The company has a licensing/development agreement with Johnson & Johnson in the United States. The drug has completed animal safety studies and small human trials, which lasted through the end of summer 1999. There is no confirmed information available yet regarding specifics on   …Continue Reading